Meeting patient needs.

We currently have three clinical candidates, filed our first IND in 2Q06 (KD3010), and anticipate subsequent IND filings in 4Q06 (KD7040) and 3Q07 (KD5170).

Cardiovascular and Metabolic Diseases

KD3010, is a PPARδ selective agonist that is currently being clinically evaluated for its ability to address the underlying causes of metabolic syndrome. More >

Pain and Inflammation

KD7040, is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. More >

Oncology

KD5170, is a histone deacetylase (HDAC) inhibitor for treatment of hematological and solid tumors. More >